

PROFESSOR MICHAEL ZITZMANN (Orcid ID : 0000-0003-3629-7160)

Article type : Review Article

Testosterone, Mood, Behaviour and Quality of Life

Michael Zitzmann

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ANDR.12867](#)

This article is protected by copyright. All rights reserved

Prof Dr med Michael Zitzmann, MD, PhD, FRSM, FECSM

This article is protected by copyright. All rights reserved

Center for Reproductive Medicine and Andrology / Clinical Andrology

University Hospital

Domagkstrasse 11

48149 Münster

Germany

Michael.Zitzmann@ukmuenster.de

Abstract

Testosterone plays a pivotal role in maintaining balance within the multi-dimensional psychological network of mood, behaviour, self-perception and perceived quality of life in men of any age. Apart from classical forms of hypogonadism, low testosterone concentrations can also be seen in older men, described as an age- as well as comorbidity-driven functional hypogonadism and might relate to depressive symptoms exhibiting a wide array of clinical pictures ranging from dysthymia and fatigue over inertia, listlessness to hopelessness and suicidal thoughts. Also various traits of anxiety, from unfocussed fear to phobic anxiousness and open panic syndromes are influenced by testosterone. Correspondingly, anxiolysis is likely to be modulated by testosterone via stress resilience, threat vigilance and reward processing. The steroid modulates pro-active and re-active dimensions of aggression, which has to be seen within the context of gaining or maintaining status. This may also include other strategies impacting the social position: heroic or parochial altruism and non-aggressive paths of assertiveness, such as posture and social vigilance. Independent rather than relationship-associated self-construal and self-esteem influence risk-taking traits under the modulation of testosterone. In addition, the genetic setting of the androgen receptor modulates the role of testosterone in aspects regarding mood and personality. Dimensions of sexuality are rather important in this context, but are not target of this article and covered in another part of this special edition. Overall, the quality of life in older hypogonadal men can be positively influenced by testosterone substitution, as has been demonstrated in large placebo-controlled trials.

Introduction

Testosterone is believed to support maintenance of psychological features representing positive and negative affects within a balance, which is perceived as “good mood” and an enjoyable quality of life. Correspondingly, a deterioration of general “good mood” and factors involved in the overall quality of life has been described as a complex of symptoms related to male hypogonadism (1-3). In older men with age- and comorbidity-related decreased serum testosterone concentrations, a condition named functional or late-onset hypogonadism, symptoms such as dysphoria, low vigour and vitality, irritability, lack of assertiveness, and depression are more likely to be present than in eugonadal men (4-6). In the European Ageing Male Study describing a cohort of elderly men, low testosterone levels were found to be associated with features of fatigue and depression (7). In agreement, men undergoing androgen-deprivation therapy for prostate cancer exhibited mood disturbances such as anxiety, fatigue and lack of vitality (8).

In the past, unprovoked aggressive behaviour and violence were found to be related to serum testosterone concentrations levels in humans and animals. Men with physically and verbally aggressive behaviour or social dominance had significantly higher levels of serum testosterone compared with non-aggressive subjects (9-11). Recently, this is seen in a more complex manner. For example, serum testosterone levels are rather associated with risk-taking behaviour and traits of reactive aggression (12-14). This effect of testosterone may be more pronounced in men exhibiting an independent self-construal, which is an individualistic view or concept of self (15). Overall, testosterone is now understood to drive a general repertoire of motivated behaviours, often subsumed under the concept of dominance behaviour. Such concepts refer to the motivation of an individual to achieve or maintain a high social status, which can also be achieved non-aggressively (16).

Thus, testosterone might influence an underlying motive rather than aggression *per se*. For instance, rhesus monkeys with high testosterone levels use stares, threats and displacements, rather than overtly aggressive interactions, to ascertain high social status (17). In humans, status is asserted on similar paths, being related to testosterone concentrations: face-to-face interactions by increased duration of staring and speech as well as body

postures displaying supremacy. In addition, acts of so-called heroic or parochial altruism, which is an increased proposer-generosity in interactions within a group to achieve a personal advantage, seem to be related to testosterone (18-21).

Hence, testosterone is a multi-faceted effector of psychological traits, ranging from general mood to modification of interaction with others.

Overall quality of life and mood

Quality of life (QoL) is a summary of psychological variables, which contribute to the subjective perception that life is worthwhile. QoL is principally the degree to which a person enjoys the possibilities of life, based on the categories "being", "belonging", and "becoming"; respectively who one is, how one is connected to one's environment, and whether one achieves one's personal goals, hopes, and aspirations. Thus, QoL is a multi-dimensional construct comprising the individual's physical, mental and social well-being, each including both cognitive and emotional components (22). Items contributing to the impression of QoL are the ability to perceive enjoyment of life in balance with perceived stress, a general motivation in life as well as overall work performance, self-confidence and the ability to focus, the subjective energy in life and the abilities to cope (22). This also includes, in most men, parameters of sexual nature. These latter are considered within another article of this issue but are, nevertheless always a part of the questionnaires recruited to estimate QoL.

A meta-analysis on testosterone replacement treatment (TRT) in hypogonadal men vs placebo evaluated 23 randomized controlled trials (21 were placebo-controlled, two were active-controlled) involving 3090 participants. Compared with placebo, treatment with any TRT significantly improved quality of life (standardized mean difference -0.26 , 95% CI -0.41 to -0.11 , $p < 0.001$). The effect was largely attenuated in men with symptoms of depression (23).

Another meta-analysis evaluated sixteen trials with a total of 944 subjects. An overall positive impact of TRT on general mood was seen with an effect size of 4.592 ($p < 0.0001$), which was age-dependent: a subgroup of men aged less than 60 years exhibited an effect size of 5.279 ($p < 0.0001$)

while the effect size was not statistically significant in men older than 60 years. The effect size in hypogonadal men was 4.192 ($p < 0.0001$), whereas the result was not statistically significant in eugonadal men. In agreement with the aforementioned analysis, the effect size was larger in with subthreshold depression compared to those with major depression (24).

Corresponding results regarding the factor “general energy” were seen in a randomized, multicenter, double-blinded, placebo-controlled, 16-week study of 715 hypogonadal symptomatic men (median age 55.3 years, range 19 to 92 years) receiving placebo or a topical testosterone solution for TRT. Patient-reported improvements in general energy using the Patient Global Impression Questionnaire showed a significant effect of TRT ($p < 0.001$). Age less than 45 years and lower baseline testosterone levels had a significant influence on a more pronounced outcome of TRT. In addition, men with forms of classical hypogonadism had a larger benefit from TRT than men with functional hypogonadism (25). As co-morbidities are found especially in functional hypogonadism and, hence, mostly in elderly men, these underlying pathologies might have, apart from hypogonadism as such, an intrinsic additional impact on QoL and psychological functions. In afflicted men, the treatment of hypogonadism is likely to attenuate symptoms, albeit not fully. Thus, it is paramount and a prerequisite that co-morbidities are treated adequately to improve QoL and wellbeing. This is in agreement with the EAA guidelines on functional hypogonadism (1).

To assess effects of TRT in older men with functional hypogonadism, a well-characterized cohort of 788 community-dwelling, relatively healthy, older men of at least 65 years of age with well-defined symptoms and with a restricted range of low testosterone levels (excluding both severely low and borderline low T levels) was recruited. Within a double-blind, placebo-controlled trial using transdermal testosterone gel, the total group using *verum* exhibited marked changes compared to placebo. Physical function as assessed by the 6-min walking test and the Physical Function Test increased significantly vs placebo ($p = 0.007$ and $p = 0.002$, respectively). Similarly, changes in the Functional Assessment of Chronic Illness Therapy (FACIT) fatigue score, the SF-36 vitality score, the PANAS positive and negative affect scores as well as the overall subjective “energy-level” were significantly improved in the total group of men receiving TRT compared to placebo. Notwithstanding, the effects were largely attenuated in a smaller subgroup selected for this analysis (26,27).

Another double-blind placebo-controlled trial focussed on older men with type 2 diabetes mellitus and simultaneously present functional hypogonadism. 199 men received intramuscular testosterone undecanoate vs placebo for 30 weeks. Measures to determine QoL were scores assessed by the Aging Male Symptom (AMS) Scale, validation of depression and anxiety based on the Hospital Anxiety and Depression Scale (HADS), and overall quality of life based on a Global Efficacy Question (GEQ). GEQ scores improved significantly in men receiving testosterone vs those receiving placebo ($p < 0.001$), while there were no significant results for the AMS and HADS domains. However, when the latter scores were stratified for clinical depression, there was a marked improvement in men receiving TRT who were not depressed (HADS: $p = 0.03$ and AMS: $p = 0.02$). This is in agreement with the meta-analysis mentioned above. Depression seems to be a major confounder on effects of TRT in hypogonadal men, when QoL is assessed (28).

Similar to this trial, positive effects of TRT on QoL were seen in larger cohorts of hypogonadal men of up to more than 1.000 patients in uncontrolled “real-life” settings or registries (29, 30). A smaller uncontrolled study comparing two different intramuscular testosterone preparations for TRT in 40 hypogonadal men described marked improvements in scales of sociability, concentration, agitation, self-confidence, listlessness, dizziness, activation, depression, fatigue, anxiety, good mood and aggression (31).

It is evident that hypogonadism can have a negative impact on quality of life and mood. Testosterone substitution is seen as a means to improve these parameters (2). However, if these psychological symptoms are the only problems of the patient, the use of TRT to improve quality of life and mood in men with hypogonadism is currently not strongly recommended (1).

Depression

Depressive symptoms, ranging from dysthymia to major depressive disorders, represent psychiatric conditions with severe personal consequences. More than 100 million men are currently affected by various forms of depression (32). Testosterone is a neuroactive steroid influencing mood and appetitive behaviour (33), which has been demonstrated by animal models of depression in which testosterone administration increased serotonin

release in the dorsal raphe nuclei as well as it induced neuroplasticity in the hippocampal formation (34-36). Both, increased serotonin release and novel neuronal connections, are central mechanisms of anti-depression, as they can promote positive patterns of thought and self-experience (37).

The European Male Aging Study demonstrated that depression in its various forms is related to hypogonadism in community-dwelling older men, with a potentially mutual causal relationship (38). Such a relation was also shown in a clinical sample of 296 older men, in whom symptoms of dysthymia, fatigue, inertia and listlessness as well as major depression were related both to serum testosterone concentrations as well as to the genetic modulation of androgen effects by the CAG repeat polymorphism within the androgen receptor gene (5,6). This is substantiated by a longitudinal investigation in 748 older men, in whom the 2-year incidence of a newly diagnosed depressive illness was 18.5% in men with previous hypogonadism vs. 10.4% in controls ($p = 0.006$). After adjustment for age and medical morbidities, men with hypogonadism had a shorter time to develop a depressive illness (adjusted hazard ratio = 2.1; 95% CI = 1.3 to 3.2, $p = 0.002$) (4).

A randomized, double-blind, placebo-controlled study in 33 hypogonadal men with a concomitant subthreshold depression (dysthymia or minor depression) investigated the effects of either testosterone gel or placebo gel. Men on TRT had a greater reduction in scores of the Hamilton Rating Scale for Depression ($p = 0.024$) and a higher remission rate of subthreshold depression (52.9% vs. 18.8%, $p = 0.041$) (39). Correspondingly, a larger double-blind placebo-controlled trial in 788 older men with functional hypogonadism (see above) improved depressive symptoms demonstrated as lowering scores on the Patient Health Questionnaire 9: the treatment effect was -0.72 (95% CI: -1.20 to -0.23) ($p = 0.004$) (26,27). Also a randomized, placebo-controlled, double-blind trial in 184 hypogonadal men receiving intramuscular testosterone undecanoate vs placebo demonstrated a marked decrease in the Beck Depression Inventory in the men receiving TRT (mean difference vs. placebo after 30 weeks: -2.5 points; 95% confidence interval [CI]: -0.9 ; -4.1 ; $P = 0.003$) (40)

A meta-analysis involving 11 placebo-controlled and 1 active-controlled trial with altogether 852 participants evaluated depression indices. Compared with placebo, any TRT improved depression (SMD -0.23 , 95% CI -0.44 to -0.01 ; $p < 0.001$) (23). Another meta-analysis included only double-blind placebo-controlled trials, which used the Hamilton Rating Scale for Depression. Seven studies involving 364 men showed a significant

positive effect of TRT in depressed patients when compared to placebo ($z = 4.04$, $p < 0.001$) (41). A recent random-effects meta-analysis of 27 randomized controlled trials including 1890 men demonstrated that TRT is associated with a significant reduction in depressive symptoms compared to placebo (Hedges $g=0.21$ [effect size according to Bessel's correction of Cohen's d]; 95%CI:0.10-0.32, $p<0.001$), showing an odds ratio of efficacy=2.30 (95%CI:1.30-4.06, $p=0.004$). These effects exceed the efficacy thresholds for pharmacologic agents for depression therapy proposed by the National Institute for Health and Care Excellence guidelines for treatment-resistant depression (42-44).

The association between testosterone and erectile function is well known, and likewise, the association between mood disorders (including depression and anxiety) and sexual dysfunction is supported by solid evidence. However, it is also true that sexual dysfunction might cause depression due to the negative psychological burden associated with it. Hence, testosterone treatment in hypogonadal patients might actually be beneficial to psychological symptoms both directly and indirectly by improving erectile function (see article about sexual function in this special edition).

Thus, symptoms of depression can be mitigated in hypogonadal men using TRT. Still preferential is the use of established anti-depressive therapies, cognitive behavioural approaches and psychiatric consultation in patients with first-line depressive symptoms or in those with diagnosed major depression (1). Nevertheless, additional testosterone supplementation can improve the outcome of such therapies if the patient is hypogonadal (42)

Anxiety

The putative associations of testosterone with anxiety and its escalating variants phobic anxiety and panic disorder have not been investigated extensively. In male rodents, induction of higher testosterone levels led to reduction in anxiety (45,46). In humans, lower testosterone concentrations and a general tendency to develop unfocussed anxiety have been described (8,47,48). An inverse correlation between symptoms of anxiety assessed with the Hopkins Symptom Checklist with total and free testosterone in a population-based sample of 3,413 men was reported (49). A correlation between testosterone and free-floating anxiety and phobic anxiety in a sample of 2,042 male patients with sexual dysfunction was

reported, as well (50). A clinical sample of 296 older men exhibited a marked association of anxiety traits (higher anxiety, panic and phobic anxiety levels) assessed with the Brief Symptom Inventory and the Patient Health Questionnaire-9 with the genetically modulated androgen activity via the CAG repeat polymorphism of the androgen receptor gene but not directly with serum testosterone levels (51).

Anxiolysis, on the other hand, might be induced by testosterone (45). The mechanisms by which testosterone might exert such effects are four suggested channels of anxiolysis: threat vigilance, reward processing, general fear reduction (leading to lower fear-related attentional bias) and stress resilience (52).

Aggression

Testosterone is often described as a pivotal moderator of aggression. There is evidence by castration and replacement experiments in animals that testosterone can drive aggression. Regarding humans, the testosterone/aggression complex is most likely not static but rather fluctuates in response to cues of challenge originating from the environment (53). Such challenge-induced fluctuations may strongly regulate situation-specific aggressive behaviour. In meta-analyses, baseline testosterone levels are weakly associated with aggression ($r = 0.071$, 95% CI:0.041-0.101). Also increments of testosterone concentrations are positively associated with aggression ($r = 0.162$, 95% CI:0.076-0.246) (53) (see below regarding anabolic steroids).

In a placebo-controlled, double-blind cross-over study using intramuscular (i.m.) injections of testosterone undecanoate (TU), 28 eugonadal men were randomized into one of two treatment groups: A1) active, receiving 1000 mg TU i.m., followed by A2) washout, followed by A3) placebo, receiving 4 ml of oily vehicle i.m.; B1) placebo, 4 ml of oily vehicle i.m.; B2) washout followed by B3) active, receiving 1000 mg TU i.m. Two-factor repeated-measures ANOVA found no significant effects on tension-anxiety, depression-dejection, vigour-activity, or confusion-bewilderment. Interaction of effects could be described for a testosterone-related increase in anger-hostility and verbal, but not physical aggression and a reduction in fatigue-inertia. In response to aggressive provocations, direct aggression increased testosterone-dependently while irritability and assertiveness

were not affected. Measures of self-esteem increased as well (54). The study has the limitation of treating eugonadal men with a single injection of testosterone, thus facilitating a change of testosterone levels that is rather subtle compared to baseline.

Self-construal as basis of competitiveness, social status, risk-taking and self-esteem

Closely related to the finding in aggressive behaviour, it appears that testosterone promotes status-seeking and social dominance motives, and thus plays an important role in social status hierarchies. A causality between social and emotional behaviour induced by testosterone might exist. Testosterone appears to have a complex role in driving behaviours that tend to increase an individual's motivation and ability to acquire as well as defend social status. Testosterone dynamics and psychopathic personality traits such as fearless dominance, coldheartedness and self-centered impulsivity independently predicting antagonistic behaviour towards persons perceived as "inferior" have been reported (55).

Such findings seem to be mediated by traits of self-construal. Self-construal refers to a person's view of self and structure of a self-schema. People with an independent self-construal hold a view of self that emphasizes the separateness of the individual, while an interdependent self-construal is associated with a self-view driven by relationships to others (56). It is assumed that a dynamic reactivity of the hypothalamic-pituitary-gonadal axis to competition might promote aggression to take risks for personal gain in the independent self, while stable and resting levels of testosterone might attenuate aggression in the interdependent self. Thus, risk-taking behaviour in men with independent self-construals seems to be reinforced by testosterone, once they have seen a success in a competition for status. It is assumed that modulations of testosterone concentrations in independent people may affect status-seeking behaviours through personalized means (using force or obtaining economic resources) whereas changes in testosterone levels in more interdependent people would prompt more socially oriented status seeking strategies (prosocial behavior, generosity) (15,57). Pharmacologically induced higher testosterone levels augmented risk-taking behaviour under time-related circumstances in men with dispositional characteristics (dominance, impulsivity, independent self-construal): time-pressure reduced cooperation and increased risk-taking, while in men with an interdependent self-construal, testosterone and time-pressure led to seeking cooperation for help (total n=400) (58).

Social status may also be gained by acts of so-called heroic or parochial altruism (being generous to gain an advantage, especially in regard to social status). Higher testosterone levels were shown to be associated with the preferential treatment of ingroup members, while aggression and discrimination was directed towards outgroup members (20). Such behavioural characteristics seem to be reflected by morphological correlates as neural responses in the anterior insula and the ventromedial prefrontal cortex can be visualized in functional magnetic resonance images during respective tasks (21).

Testosterone effects on behaviour are modulated by the androgen receptor gene CAG repeat polymorphism, as a psychopharmacogenetic approach in 308 men with independent self-construals revealed. Men with shorter repeats experienced a greater reward of testosterone-induced assertive behaviour (59). This is corroborated by another study, in which higher testosterone levels and shorter CAG repeats were related to dominance as well as aggressive and non-aggressive risk-taking, while longer CAG repeats and lower testosterone were related to depression and lower self-esteem (60). Similarly, short CAG repeats and higher testosterone levels were associated with measures of impulsivity in younger men: motor impulsiveness, cognitive impulsiveness and non-planning impulsiveness (61). Higher testosterone levels and shorter androgen receptor gene CAG repeats are also associated with confidence and competitiveness in men (62). Correspondingly, in a pharmacological trial in 173 men, exogenous testosterone vs. placebo increased motivation to compete for status, but only in individuals with an unstable low status or a stable high status and short CAG repeats. Men with a stable low status refrained from competition regardless of testosterone and genetic background (63).

The question arises whether any evidence regarding differences between men with congenital and acquired hypogonadism in relation to behavioural characteristics exists. While it seems quite plausible that such differences could be present, there is no reliable research on this matter. One might assume, however, that men with congenital hypogonadism exhibit a different spectrum of behavioural traits than men with acquired forms of hypogonadism as they have never experienced and learned from the consequences of various types of androgen-related behaviour (64, 65).

Effect of anabolic steroids on mood and behaviour

There is a widespread abuse of synthetic anabolic steroids which are metabolized differently compared to natural testosterone, e.g. these substances might not be aromatized or 5-alpha-reduced or might have intrinsic other binding capacities to receptors. An assumed side effect of anabolic androgenic steroids (AASs) is an induction of impulsive and uncontrolled behaviour, characterized by indiscriminate and (un-)provoked aggression (so-called 'roid rage'). Pubertal rats receiving AASs respond to social cues more aggressively toward intact males than do castrated controls. AASs might sensitize these animals to their surroundings and lower the threshold to respond to provocation with aggression. It was thus speculated that in humans, AAS exposure does not function as a proximal trigger for violence, but may increase the likelihood that aggressive reactions to provocation will result in violence, i.e. physical aggression eventually transforming into massive, harmful hostility („...when the monkey is high, you do not stare...“). Since there are only case reports about 'roid-rage', this subject remains debatable (66-69). However, it has been demonstrated among adolescents, that psychiatric disorders, such as conduct disorders and sociopathies, can promote the switch to abuse AASs, thus being a trigger and not the result of AAS use (70). Nevertheless, apart from the dimension of aggression, reports exist that AAS use can lead to profound effects on the brain and behaviour inducing poor impulse controls of anxiety and promote extreme mood swings from depression to mania or hypomania (71-75). There are reports that sleeplessness, increased irritability, depression disorders as well as melancholy and anxiety may persist for many years in AAS users and former users (76). Speculations exist that such processes have a morphological substrate in form of a lower connectivity between amygdala and frontal, striatal, limbic, hippocampal and visual cortical areas (77).

Summary

In men, mood, behaviour and quality of life are influenced by testosterone. Marked effects on mood and behaviour can be facilitated by endogenous testosterone levels and external administration of the sex steroid. Such effects are likely to be mediated genetically by the CAG repeat androgen receptor polymorphism. Not all findings are robust, but it can be assumed that the multi-faceted effects of testosterone, as summarized in Figure 1,

can be influenced by low testosterone levels as found in hypogonadism and may be subject to restoration by testosterone replacement therapy. Well-being and quality of life in men are a function of testosterone.

Legend to Figure 1

Characteristics of mood, behaviour and quality of life as being influenced by testosterone levels

References

1. Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. 2020 epub
2. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. EAU guidelines on male hypogonadism 2018. <https://uroweb.org/guideline/male-hypogonadism/?type=summary-of-changes> last access 04JUN2020
3. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 103:1715-1744
4. Shores MM, Mocerri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 2005;66:7–14
5. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology. 2010 May;35:578-87
6. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry. 2011 Mar;19(3):274-83
7. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–35
8. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the 'androgen deprivation syndrome' in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006;166:465–71
9. Olweus D, Mattsson A, Schalling D, et al . Testosterone, aggression, physical violence, and personality dimensions in normal adolescent males. Psychosom Med 1980;42:253–69. 42.

10. Su T-P, Pagliaro M, Schmidt PJ, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. *JAMA* 1993;269:2760–4.40–42
11. Dabbs Jr JM, Frady RL, Carr TS. Saliva testosterone and criminal violence in young adult prison inmates. *Psychosomatic Medicine* 1987;49:174–82
12. Apicella, C. L., Dreber, A., & Mollerstrom, J. (2014). Salivary testosterone change following monetary wins and losses predicts future financial risk-taking. *Psychoneuroendocrinology*, 39, 58-64
13. Carré, J. M., Campbell, J. A., Lozoya, E., Goetz, S. M. M., & Welker, K. M. (2013). Changes in testosterone mediate the effect of winning on aggressive behavior. *Psychoneuroendocrinology*, 38(10), 2034–2041
14. Carré, J. M., Geniole, S. N., Ortiz, T. L., Bird, B. M., Videto, A., & Bonin, P. L. (2017). Exogenous testosterone rapidly increases aggressive behavior in dominant and impulsive men. *Biological Psychiatry* 82(4): 249-256
15. Welker, K. M., Norman, R., Goetz, S. M. M., Kitayama, S., & Carré, J. M. (2017). Preliminary evidence that testosterone's association with aggressive behaviour depends on self-construal. *Hormones and Behavior*, 92, 117–12
16. Mazur, A. and Booth, A. (1998) Testosterone and dominance in men. *Behav. Brain Sci.* 21, 353–363 discussion 363–397
17. Higley, J.D. CSF, testosterone and 5-HIAA correlate with different types of aggressive behaviors. *Biol. Psychiatry* 1996 40, 1067–1082
18. Eisenegger C, Haushofer J, Fehr E. The role of testosterone in social interaction. *Trends Cogn Sci.* 2011 Jun;15(6):263-71;
19. Diekhof EK, Wittmer S, Reimers L. Does competition really bring out the worst? Testosterone, social distance and inter-male competition shape parochial altruism in human males. *PLoS One.* 2014 Jul 30;9(7):e98977
20. Reimers L, Kappo E, Stadler L, Yaqubi M, Diekhof EK. Endogenous testosterone correlates with parochial altruism in relation to costly punishment in different social settings. *PeerJ.* 2019 Aug 28;7:e7537;
21. Reimers L, Büchel C, Diekhof EK. Neural substrates of male parochial altruism are modulated by testosterone and behavioral strategy. *Neuroimage.* 2017 Aug 1;156:265-276
22. Testa MA, Simonson DC. Assessment of quality of life outcomes. *N Engl J Med* 1996; 334: 835±840

23. Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, Kotb A, Skidmore B, Bai Z, Mamdani M, Wells GA. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. *BMJ Open*. 2017 16:e015284
24. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. *Ann Clin Psychiatry*. 2014 Feb;26(1):19-32
25. Wu F, Zitzmann M, Heiselman D, Donatucci C, Knorr J, Patel AB, Kinchen K. Demographic and Clinical Correlates of Patient-Reported Improvement in Sex Drive, Erectile Function, and Energy With Testosterone Solution 2. *J Sex Med*. 2016 Aug;13(8):1212-9
26. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. *N Engl J Med*. 2016 Feb 18;374(7):611-24
27. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS. Lessons From the Testosterone Trials. *Endocr Rev*. 2018 Jun 1;39(3):369-386.
28. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. *J Sex Med*. 2013 Jun;10(6):1612-27
29. Zitzmann M, Mattern A, Hanisch J, Looren L, Jones H, Maggi M. IPASS, a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. *J Sex Med* 2012;10:579–88
30. Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, Romero-Otero J, Martinez-Salamanca JI, Jones TH, Debruyne FMJ, Kurth KH, Hackett GI, Quinton R, Stroberg P, Reisman Y, Pescatori ES, Morales A, Bassas L, Cruz N, Cunningham GR, Wheaton OA; RHYME

- Investigators. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). *J Sex Med.* 2017 Sep;14(9):1104-1115
31. Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Ernst M. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. *Eur J Endocrinol.* 2009 May;160(5):815-9
32. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. *Psychol Bull.* 2017;143(8):783-822
33. Amiaz R, Seidman SN. Testosterone and depression in men. *Curr Opin Endocrinol Diabetes Obes.* 2008;15(3):278-283
34. Gould TD, Georgiou P, Brenner LA, et al. Animal models to improve our understanding and treatment of suicidal behavior. *Transl Psychiatry.* 2017;7(4):e1092
35. Carrier N, Saland SK, Duclot F, He H, Mercer R, Kabbaj M. The anxiolytic and antidepressant-like effects of testosterone and estrogen in gonadectomized male rats. *Biol Psychiatry.* 2015;78 (4):259-269
36. Wainwright SR, Workman JL, Tehrani A, et al. Testosterone has antidepressant-like efficacy and facilitates imipramine-induced neuroplasticity in male rats exposed to chronic unpredictable stress. *Horm Behav.* 2016;79:58-69.
37. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. *Neural Plast.* 2007;2007:73754.
38. Wu FCW, Tajar A, Beynon JM, et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010; 363(2):123-135
39. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression) *J Clin Psychiatry.* 2009 Jul;70(7):1009-16
40. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. *J Sex Med.* 2010 7:2572-82

41. Zarrouf FA, Artz S, Griffith J, Sirbu C, Komor M. Testosterone and depression: systematic review and meta-analysis. *J Psychiatr Pract*. 2009 15:289-305
42. Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. *JAMA Psychiatry*. 2019;76:31-40
43. National Collaborating Centre for Mental Health UK. Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester, UK: British Psychological Society;2010
44. Button KS, Kounali D, Thomas L. Minimal clinically important difference on the Beck Depression Inventory–II according to the patient's perspective. *Psychol Med*. 2015;45:3269-3279
45. Frye CA, Seliga A. Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats. *Cogn Affect Behav Neurosci* 2001;1:371–81
46. Aikey JL, Nyby JG, Anmuth DM, James PJ. Testosterone rapidly reduces anxiety in male house mice (*Mus musculus*). *Horm Behav* 2002;42:448–60
47. Diamond P, Brisson G, Candas B, Peronnet F. Trait anxiety, submaximal physical exercise and blood androgens. *Eur J Appl Physiol Occup Physiol* 1989;58:699–704
48. Granger DA, Shirtcliff EA, Zahnwaxler C, Usher B, Klimes-Dougan B, Hastings P. Salivary testosterone diurnal variation and psychopathology in adolescent males and females: Individual differences and developmental effects. *Dev Psychopathol* 2003;15:431–49
49. Berglund LH, Prytz HS, Perski A, Svartberg J. Testosterone levels and psychological health status in men from a general population: The Tromsø study. *Aging Male* 2011;14:37–41
50. Bandini E, Corona G, Ricca V, Fisher AD, Lotti F, Sforza A, Faravelli C, Forti G, Mannucci E, Maggi M. Hysterical traits are not from the uterus but from the testis: A study in men with sexual dysfunction. *J Sex Med* 2009;6:2321–31
51. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in ≥50-year-old males. *J Sex Med*. 2011 8:3452-64

52. Eisenegger C, Haushofer J, Fehr E. The role of testosterone in social interaction. *Trends Cogn Sci*. 2011 15:263-71
53. Geniole SN, Bird BM, McVittie JS, Purcell RB, Archer J, Carré JM. Is testosterone linked to human aggression? A meta-analytic examination of the relationship between baseline, dynamic, and manipulated testosterone on human aggression. *Horm Behav*. 2019 28:104644
54. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. *J Clin Endocrinol Metab*. 2004 Jun;89(6):2837-45
55. Geniole SN, Busseri MA, McCormick CM. Testosterone Dynamics and Psychopathic Personality Traits Independently Predict Antagonistic Behavior Towards the Perceived Loser of a Competitive Interaction. *Horm Behav* . 2013 64:790-8
56. Cross SE, Hardin EE, Gercek-Swing B. The what, how, why, and where of self-construal. *Pers Soc Psychol Rev*. 2011 May;15(2):142-79
57. Welker KM, Roy ARK, Geniole S, Kitayama S, Carré JM Taking risks for personal gain: An investigation of self-construal and testosterone responses to competition. *Soc Neurosci*. 2019 Feb;14(1):99-113
58. Bird BM, Geniole SN, Procyshyn TL, Ortiz TL, Carré JM, Watson NV. Effect of exogenous testosterone on cooperation depends on personality and time pressure. *Neuropsychopharmacology*. 2019 44:538-545
59. Geniole SN, Procyshyn TL, Marley N, Ortiz TL, Bird BM, Marcellus AL, Welker KM, Bonin PL, Goldfarb B, Watson NV, Carré JM. Using a Psychopharmacogenetic Approach To Identify the Pathways Through Which-and the People for Whom-Testosterone Promotes Aggression. *Psychol Sci*. 2019 Apr;30(4):481-494
60. Vermeersch H, T'Sjoen G, Kaufman JM, Vincke J, Van Houtte M. Testosterone, androgen receptor gene CAG repeat length, mood and behaviour in adolescent males. *Eur J Endocrinol*. 2010 Aug;163(2):319-28.
61. Aluja A, García LF, Martí-Guiu M, Blanco E, García O, Fibla J, Blanch À. Interactions among impulsiveness, testosterone, sex hormone binding globulin and androgen receptor gene CAG repeat length. *Physiol Behav*. 2015 147:91-6
62. Eisenegger C, Kumsta R, Naef M, Gromoll J, Heinrichs M. Testosterone and androgen receptor gene polymorphism are associated with confidence and competitiveness in men. *Horm Behav*. 2017 92:93-102

63. Losecaat Vermeer AB, Krol I, Gausterer C, Wagner B, Eisenegger C, Lamm C. Exogenous testosterone increases status-seeking motivation in men with unstable low social status. *Psychoneuroendocrinology*. 2020 113:104552
64. Cohen J, Nassau DE, Patel P, Ramasamy R. Low Testosterone in Adolescents & Young Adults. *Front Endocrinol (Lausanne)*. 2020 Jan 10;10:916
65. Andrea Salonia, Giulia Rastrelli, Geoffrey Hackett, Stephanie B. Seminara, Ilpo T. Huhtaniemi, Rodolfo A. Rey, Wayne J. G. Hellstrom, Mark R. Palmert, Giovanni Corona, Gert R. Dohle, Mohit Khera, Yee-Ming Chan, Mario Maggi. Paediatric and adult-onset male hypogonadism. *Nat Rev Dis Primers*. 2019 5: 38
66. McGinnis MY Anabolic androgenic steroids and aggression: studies using animal models. *Ann N Y Acad Sci*. 2004 1036:399-415
67. Robby Williams. Me and My Monkey. 2002. Song lyrics
68. Sansone A, Sansone M, Vaamonde D, Sgrò P, Salzano C, Romanelli F, Lenzi A, Di Luigi L. Sport, doping and male fertility. *Reprod Biol Endocrinol*. 2018 16(1):114
69. Sansone A, Sansone M, Lenzi A, Romanelli F. Testosterone Replacement Therapy: The Emperor's New Clothes. *Rejuvenation Res*. 2017 20:9-14
70. Kanayama G, Pope HG, Hudson JI. Associations of Anabolic-Androgenic Steroid Use with Other Behavioral Disorders: An Analysis Using Directed Acyclic Graphs. *Psychol. Med*. 2018 48:2601-2608
71. Hall RCW, Hall RCW, Chapman MJ. Psychiatric complications of anabolic steroid abuse *Psychosomatics*. 2005 46:285-90.
72. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric Side Effects Induced by Supraphysiological Doses of Combinations of Anabolic Steroids Correlate to the Severity of Abuse. *Eur. Psychiatry*. 2006. 21:551-62.
73. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN. Psychiatric and Hostility Factors Related to Use of Anabolic Steroids in Monozygotic Twins. *Eur. Psychiatry*. 2006 21:563-9
74. Trenton AJ, Currier GW. Behavioural Manifestations of Anabolic Steroid Use. *CNS Drugs*. 2005 19:571-95

75. Lundholm L, Käll K, Wallin S, Thiblin I. Use of Anabolic Androgenic Steroids in Substance Abusers Arrested for Crime. *Drug Alcohol Depend.* 2010 111(3):222-6
76. Vorona E, Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. *Minerva Endocrinol.* 2018 Dec;43(4):476-488
77. Bertozzi G, Salerno M, Pomara C, Sessa F. Neuropsychiatric and Behavioral Involvement in AAS Abusers. A Literature Review. *Medicina (Kaunas).* 2019 55:396.

